Doctor profile · Federal record
Dr. Paul Zito, MBBS
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Internal Medicine Physician · Internal Medicine Physician · Tulsa, OK
- NPI 1396155966
- Accepts Medicare
- MIPS 82.5 / 100 · 2023
- 13 yrs in practice
- Licensed in 3 states
- Male
- Solo practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
Oklahoma Cancer Specialist & Research Institute, 12697 E 51St St 5Th
Tulsa, OK 74146
(918) 505-3200
fax (918) 505-3225 - Additional location
-
100 Medical Center Dr
Slidell, LA 704615520
(985) 646-5750
fax (985) 646-5098
Credentials & registration
- NPI registered
- May 2014 — 12 yrs on file
- Profile last updated
- December 23, 2025
- Year of graduation
- 2013 — 13 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State licenses (3)
- Oklahoma #38114 · Louisiana #309958 · Texas #R3253
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1396155966. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
178,528
Distinct HCPCS
10
Medicare allowed
$2,776,327
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J1439 |
Injection, ferric carboxymaltose, 1 mg | 24,000 | 30 | $1 | |
J9299 |
Injection, nivolumab, 1 mg | 16,920 | 27 | $30 | |
Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,750 | 170 | $0 | |
Q5110 |
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 13,980 | 16 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 11,000 | 35 | $54 | |
J1627 |
Injection, granisetron, extended-release, 0.1 mg | 10,400 | 81 | $6 | |
J9267 |
Injection, paclitaxel, 1 mg | 10,377 | 45 | $0 | |
J9025 |
Injection, azacitidine, 1 mg | 8,300 | 11 | $0 | |
J0185 |
Injection, aprepitant, 1 mg | 7,930 | 52 | $2 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 7,500 | 20 | $0 |
In context: peer comparison
Among 18 peers in this city , average services per provider: 1,283. This provider delivers 139× the peer median.Open Payments
Industry payments received
All-time total
$829
Transactions
30
Manufacturers
12
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| PFIZER INC. | 13 | $171.59 | |
| AstraZeneca Pharmaceuticals LP | 3 | $161.33 | |
| INTUITIVE SURGICAL, INC. | 1 | $129.89 | |
| Blueprint Medicines Corporation | 1 | $121.81 | |
| Ipsen Biopharmaceuticals, Inc | 4 | $64.92 | |
| Novartis Pharmaceuticals Corporation | 2 | $35.79 | |
| Genmab U.S., Inc. | 1 | $33.16 | |
| E.R. Squibb & Sons, L.L.C. | 1 | $28.96 | |
| Karyopharm Therapeutics Inc. | 1 | $23.22 | |
| Janssen Biotech, Inc. | 1 | $23.12 | |
| Daiichi Sankyo Inc. | 1 | $22.32 | |
| Eisai Inc. | 1 | $13.14 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,007
Patients
462
Total drug cost
$51,158
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 221 | 78 | $7,670 |
| Prochlorperazine Maleate | Generic | 96 | 58 | $1,032 |
| Ondansetron Hcl | Generic | 93 | 55 | $1,048 |
| Dexamethasone | Generic | 76 | 43 | $1,386 |
| Levofloxacin | Generic | 71 | 58 | $352 |
| Prednisone | Generic | 63 | 24 | $437 |
| Levothyroxine Sodium | Generic | 57 | 19 | $514 |
| Eliquis (Apixaban) | Brand | 56 | 13 | $33,917 |
| Acyclovir | Generic | 48 | 13 | $530 |
| Potassium Chloride | Generic | 43 | 18 | $778 |
Hospital affiliations
Frequently asked questions
What is Dr. Paul Zito's medical specialty?
Dr. Paul Zito practices Hematology & Oncology Physician in Tulsa, OK.
Where does Dr. Paul Zito practice?
Dr. Paul Zito practices at Oklahoma Cancer Specialist & Research Institute, Tulsa, OK 74146. Office phone: 9185053200.
What is Dr. Paul Zito's NPI?
Dr. Paul Zito's National Provider Identifier (NPI) is 1396155966, issued by NPPES.
Does Dr. Paul Zito accept Medicare assignment?
Yes. Dr. Paul Zito accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Paul Zito commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferric carboxymaltose, 1 mg (HCPCS J1439); Injection, nivolumab, 1 mg (HCPCS J9299); Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS Q9967). Source: CMS Medicare Physician & Other Practitioners file.